Titan Pharmaceuticals Inc TTNP
We take great care to ensure that the data presented and summarized in this overview for TITAN PHARMACEUTICALS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding TTNP
View allLatest Institutional Activity in TTNP
Top Purchases
Top Sells
About TTNP
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union. It is also developing kappa opioid agonist peptide program (TP-2021) for use in combination with ProNeura technology for the treatment of chronic pruritus; nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California.
Insider Transactions at TTNP
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 18
2024
|
Choon Hau Choong > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
54,132
+1.4%
|
-
|
|
Oct 25
2023
|
Eric Howard Greenberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,250
+19.7%
|
-
|
|
Oct 25
2023
|
Matthew Charles Mc Murdo Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,250
+19.7%
|
-
|
|
Oct 25
2023
|
David Natan Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,250
+19.7%
|
-
|
|
Oct 25
2023
|
Katherine Beebe President and COO |
BUY
Grant, award, or other acquisition
|
Direct |
16,250
+19.7%
|
-
|
|
Oct 25
2023
|
Avraham Ben Tzvi Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,250
+19.7%
|
-
|
|
Jul 26
2023
|
Eric Howard Greenberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+50.0%
|
-
|
|
Jul 26
2023
|
David E. Lazar Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+50.0%
|
-
|
|
Jul 26
2023
|
Avraham Ben Tzvi Director |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+50.0%
|
-
|
|
Jul 26
2023
|
Katherine Beebe President and COO |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+50.0%
|
-
|
|
Jul 26
2023
|
Peter Louis Chasey Director |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+50.0%
|
-
|
|
Jul 26
2023
|
David Natan Director |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+50.0%
|
-
|
|
Jul 26
2023
|
Matthew Charles Mc Murdo Director |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+50.0%
|
-
|
|
Jun 21
2023
|
David E. Lazar Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
359,066
-100.0%
|
$359,066
$1.23 P/Share
|
|
Jun 21
2023
|
David E. Lazar Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
3,388,902
-100.0%
|
$3,388,902
$1.23 P/Share
|
|
Jan 25
2023
|
David E. Lazar Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
20,000
+0.59%
|
$20,000
$1.0 P/Share
|
|
Jan 24
2023
|
David E. Lazar Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
37,500
+1.1%
|
$0
$0.97 P/Share
|
|
Jul 07
2022
|
David E. Lazar Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
744,294
+18.26%
|
$0
$0.99 P/Share
|
|
Jul 06
2022
|
David E. Lazar Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
315,921
+46.8%
|
$0
$0.89 P/Share
|
|
Jul 06
2022
|
David E. Lazar Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
1,165,975
+31.07%
|
$0
$0.77 P/Share
|
Last 12 Months Summary
| Conversion of derivative security | 54.1K shares |
|---|